Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study

Mortality reduction in critically ill subjects at 28 days revised favorably, statistically significantEB05 demonstrated an 84% reduction in the risk of dying when compared to placeboClinical Study Report submitted to FDATORONTO, ON / ACCESSWIRE / …